2011
DOI: 10.1373/clinchem.2010.156901
|View full text |Cite
|
Sign up to set email alerts
|

Personalized Medicine in Diabetes

Abstract: BACKGROUND:Multiple genes that are associated with the risk of developing diabetes or the risk of diabetes complications have been identified by candidate gene analysis and genomewide scanning. These molecular markers, together with clinical data and findings from proteomics, metabolomics, pharmacogenetics, and other methods, lead to a consideration of the extent to which personalized approaches can be applied to the treatment of diabetes mellitus.CONTENT: Known genes that cause monogenic subtypes of diabetes … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
44
0

Year Published

2011
2011
2021
2021

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 63 publications
(45 citation statements)
references
References 63 publications
1
44
0
Order By: Relevance
“…It is widely believed that a key factor for future improvements in disease treatment will be driven by point-of-care and home-based diagnostics linked with genetic testing and emerging technologies such as proteomics and metabolomics analysis (Malandrino and Smith, 2011). This has led to the concept of personalized medicine, which foresees the customization of healthcare to an individual patient (Holmes et al, 2010;Scoutaris et al, 2011).…”
Section: Introductionmentioning
confidence: 99%
“…It is widely believed that a key factor for future improvements in disease treatment will be driven by point-of-care and home-based diagnostics linked with genetic testing and emerging technologies such as proteomics and metabolomics analysis (Malandrino and Smith, 2011). This has led to the concept of personalized medicine, which foresees the customization of healthcare to an individual patient (Holmes et al, 2010;Scoutaris et al, 2011).…”
Section: Introductionmentioning
confidence: 99%
“…T2D is a polygenic disease, and several single nucleotide polymorphisms (SNPs) have been associated with risk or protection regarding this disease and its complications (3)(4)(5).…”
Section: Introductionmentioning
confidence: 99%
“…Thus, whether one pharmacological approach is more favourable than another one (GLP-1 receptor agonist versus DPP-4 inhibitor as considered here or the reverse) would probably depend on the pathophysiological and other clinical characteristics of each individual patient. It is anticipated that strategies for individualized treatment decisions will emerge with expanding knowledge of polygenic factors and other molecular determinants of disease [43].…”
Section: Which Incretin-based Therapy Is the Most Favourable? Is It Rmentioning
confidence: 99%